Morton S J, Powell R J
Clinical Immunology Unit, University Hospital, Queens Medical Centre, Nottingham, UK.
Ann Rheum Dis. 2000 Jun;59(6):487-9. doi: 10.1136/ard.59.6.487.
To establish the usefulness of cyclosporin for systemic lupus erythematosus (SLE) in a routine clinical setting.
Patients who had received cyclosporin for SLE, mixed connective tissue disease, and other overlap syndromes were identified. Data relating to treatment with cyclosporin, including dosage, concurrent steroid use, response to treatment, side effects, and reasons for withdrawal, were extracted from medical notes.
A total of 43 patients had been treated with cyclosporin between 1995 and 1998. Cyclosporin, average dose 4 mg/kg/d, was started in patients whose disease was active despite previous use of alternative second line agents. On every occasion when cyclosporin was used for thrombocytopenia the response was good, but when arthritis was the indication, the response was good in 14/26. The success rates for symptoms of arthralgia, myalgia, and fatigue were lower. Side effects occurred in 28/43 (65%) cases, and on 39/47 (83%) occasions cyclosporin was withdrawn owing to either side effects or failure to control disease activity, after a median duration of treatment of only four months.
The response to cyclosporin is mixed and usually short lived.
在常规临床环境中确定环孢素治疗系统性红斑狼疮（SLE）的有效性。
确定接受环孢素治疗SLE、混合性结缔组织病及其他重叠综合征的患者。从病历中提取与环孢素治疗相关的数据，包括剂量、同时使用的类固醇、治疗反应、副作用及停药原因。
1995年至1998年间共有43例患者接受环孢素治疗。尽管先前使用过其他二线药物，但疾病仍活跃的患者开始使用环孢素，平均剂量为4mg/kg/d。每次使用环孢素治疗血小板减少症时反应良好，但用于关节炎时，26例中有14例反应良好。关节痛、肌痛和疲劳症状的成功率较低。28/43（65%）例出现副作用，在治疗中位持续时间仅4个月后，39/47（83%）次因副作用或未能控制疾病活动而停用环孢素。
对环孢素的反应不一，且通常持续时间较短。
